BACKGROUND: The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them to the interior of the cell is important for the identification of novel potential targets for therapeutic intervention. DESIGN AND METHODS: We compared the gene expression profiles of chronic lymphocytic leukemia B cells purified from bone marrow and peripheral blood to identify genes that are induced by the bone marrow microenvironment. Two of the differentially expressed genes were further studied in cell culture experiments and in an animal model to determine whether they could represent appropriate therapeutic targets in chronic lymphocytic leukemia. RESULTS: Functional classification analysis revealed that the majority of differentially expressed genes belong to gene ontology categories related to cell cycle and mitosis. Significantly up-regulated genes in bone marrow-derived tumor cells included important cell cycle regulators, such as Aurora A and B, survivin and CDK6. Down-regulation of Aurora A and B by RNA interference inhibited proliferation of chronic lymphocytic leukemia-derived cell lines and induced low levels of apoptosis. A similar effect was observed with the Aurora kinase inhibitor VX-680 in primary chronic lymphocytic leukemia cells that were induced to proliferate by CpG-oligonucleotides and interleukin-2. Moreover, VX-680 significantly blocked leukemia growth in a mouse model of chronic lymphocytic leukemia. CONCLUSIONS: Aurora A and B are up-regulated in proliferating chronic lymphocytic leukemia cells and represent potential therapeutic targets in this disease.
BACKGROUND: The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them to the interior of the cell is important for the identification of novel potential targets for therapeutic intervention. DESIGN AND METHODS: We compared the gene expression profiles of chronic lymphocytic leukemia B cells purified from bone marrow and peripheral blood to identify genes that are induced by the bone marrow microenvironment. Two of the differentially expressed genes were further studied in cell culture experiments and in an animal model to determine whether they could represent appropriate therapeutic targets in chronic lymphocytic leukemia. RESULTS: Functional classification analysis revealed that the majority of differentially expressed genes belong to gene ontology categories related to cell cycle and mitosis. Significantly up-regulated genes in bone marrow-derived tumor cells included important cell cycle regulators, such as Aurora A and B, survivin and CDK6. Down-regulation of Aurora A and B by RNA interference inhibited proliferation of chronic lymphocytic leukemia-derived cell lines and induced low levels of apoptosis. A similar effect was observed with the Aurora kinase inhibitor VX-680 in primary chronic lymphocytic leukemia cells that were induced to proliferate by CpG-oligonucleotides and interleukin-2. Moreover, VX-680 significantly blocked leukemia growth in a mouse model of chronic lymphocytic leukemia. CONCLUSIONS: Aurora A and B are up-regulated in proliferating chronic lymphocytic leukemia cells and represent potential therapeutic targets in this disease.
Authors: Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd Journal: Blood Date: 2011-03-21 Impact factor: 22.113
Authors: Ke Lin; Mark A Glenn; Robert J Harris; Andrew D Duckworth; Sally Dennett; John C Cawley; Mirko Zuzel; Joseph R Slupsky Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Michela Tarnani; Luca Laurenti; Pablo G Longo; Nicola Piccirillo; Stefania Gobessi; Alice Mannocci; Sara Marietti; Simona Sica; Giuseppe Leone; Dimitar G Efremov Journal: Leuk Res Date: 2010-01-13 Impact factor: 3.156
Authors: Stefano Ferrari; Oriano Marin; Mario A Pagano; Flavio Meggio; Daniel Hess; Mahmoud El-Shemerly; Agnieszka Krystyniak; Lorenzo A Pinna Journal: Biochem J Date: 2005-08-15 Impact factor: 3.857
Authors: Yijiang Shi; Tony Reiman; Weiqun Li; Christopher A Maxwell; Subrata Sen; Linda Pilarski; Tracy R Daniels; Manuel L Penichet; Rick Feldman; Alan Lichtenstein Journal: Blood Date: 2007-01-09 Impact factor: 22.113
Authors: Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Sarah Picaud; David Da Costa; Angeliki Thanasopoulou; Panagis Filippakopoulos; Paul V Fish; Martin Philpott; Oleg Fedorov; Paul Brennan; Mark E Bunnage; Dafydd R Owen; James E Bradner; Philippe Taniere; Brendan O'Sullivan; Susanne Müller; Juerg Schwaller; Tatjana Stankovic; Stefan Knapp Journal: Cancer Res Date: 2013-04-10 Impact factor: 12.701
Authors: Phuong-Hien Nguyen; Tamina Seeger-Nukpezah; Lisa Rusyn; Sebastian Reinartz; Anastasia Nikiforov; Nelly Mikhael; Alexander Vom Stein; Viktoria Kohlhas; Johannes Bloehdorn; Stephan Stilgenbauer; Philipp Lohneis; Reinhard Buettner; Sandra Robrecht; Kirsten Fischer; Christian Pallasch; Michael Hallek Journal: Leukemia Date: 2022-05-06 Impact factor: 12.883
Authors: Denise Risnik; Enrique Podaza; María B Almejún; Ana Colado; Esteban E Elías; Raimundo F Bezares; Horacio Fernández-Grecco; Santiago Cranco; Julio C Sánchez-Ávalos; Mercedes Borge; Romina Gamberale; Mirta Giordano Journal: Sci Rep Date: 2017-11-16 Impact factor: 4.379